Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Background Tislelizumab is an investigational, humanized, IgG4 monoclonal antibody with high affinity and binding specificity for programmed cell death-1 (PD-1) that was engineered to minimize binding to FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell...

Full description

Saved in:
Bibliographic Details
Main Authors: Lin Shen, Qing Zhou, Ting Sun, Jie Wang, Hongming Pan, Yi-Long Wu, Jun Zhao, Jun Guo, Qingyuan Zhang, Ying Yuan, Yuxian Bai, Tianshu Liu, Yongqian Shu, Siyang Wang, Aiping Zhou, Dingwei Ye, Yujuan Gao, Silu Yang, Zuobai Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000437.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/1/e000437.full

Similar Items